Gilead Sciences (NASDAQ:GILD) Completes Acquisition of YM BioSciences (YMI) – GILD, MRK, BMY, JNJ

Gilead Sciences, Inc (NASDAQ:GILD) reported on Friday that it has done it’s almost $510 million purchase of Mississauga, Canada-based YM BioSciences Inc (USA) (NYSEAMEX:YMI).

Biopharmaceuticals firm Gilead reported that its subsidiary has purchased all of the outstanding common shares of YM pursuant to the terms of a scheme of plan. After the purchase of shares, YM has turn to a wholly-owned business of Gilead.

In December, Gilead Sciences decided to purchase YM in an action to gain access to YM research for a chronic bone-marrow disorder known as myelofibrosis.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Merck & Co., Inc. (NYSE:MRK) rose +0.44% to settle at $41.18, Bristol Myers Squibb Co. (NYSE:BMY) moved up +1.48% to end at $37.03 while Johnson & Johnson (NYSE:JNJ) jumped +0.56% to finish at $75.48 on Friday.

Gilead Sciences, Inc. (NASDAQ:GILD) last session’s volume of 8.97 million shares was surprisingly lower than its average volume of 9.00 million shares. The stock after opening at $40.32 hit high price of $41.27 and then closed at $40.90 by scoring +1.34%.

The liquidity measure in recent quarter results of the company was recorded 1.22 as current ratio and on the other side the debt to equity ratio was 1.02 and long-term debt to equity ratio remained at 0.82. The Company had total cash of $2.58 billion at hand and a book value per share as $6.29 in the most recent quarter.

The stock’s price volatility was 2.89% for a week and 2.05% for a month as well as price volatility’s Average True Range for 14 days was 0.91 and its beta remained at 0.47.

GILD generated revenue of $9.31 billion in the previous twelve months and earned $2.49 billion. The Company showed a positive 26.59% in the net profit margin as well as in its operating margin which remained at 40.40%. Company’s annual sales growth for the past five years was 22.61%.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.